Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
ORIGINAL ARTICLES
Efficacy and Safety of Formoterol in Japanese Patients with COPD
Yoshiaki MinakataHideya IijimaTsuneyuki TakahashiMotohiko MiuraHiromasa OgawaKeiji KimuraTakeharu KogaMasaharu KinoshitaTohru TsudaHisamichi AizawaMasakazu Ichinose
Author information
JOURNAL OPEN ACCESS

2008 Volume 47 Issue 4 Pages 217-223

Details
Abstract

Objective This study evaluated the efficacy and safety of the formoterol Turbuhaler® at dosages of 4.5, 9 and 18 μg bid compared with placebo in Japanese patients with COPD.
Methods In this randomized, double-blind, placebo-controlled, multicenter study, 36 patients with a pre-bronchodilator FEV1 value within 40 to 70% of the predicted value were randomized to receive formoterol at doses of 4.5, 9, and 18 μg bid, and placebo, for 1 week in a crossover fashion.
Results The primary outcome variable, one hour post-dose FEV1 on the last day of the one week treatment period, was significantly higher for all formoterol dosages compared with placebo (p<0.001 for all doses); adjusted g-means for formoterol 4.5, 9 and 18 μg bid, and placebo, were 1.510 L, 1.491 L, 1.520 L and 1.342 L, respectively. All three dosages of formoterol also provided significantly better improvements than placebo in the secondary variables FVC, inspiratory capacity (IC) and morning and evening PEF. Results for IC and PEF indicated a trend towards a larger improvement at higher dosages.
Conclusion Treatment with formoterol at dosages of 4.5, 9 and 18 μg bid showed significantly superior effects to placebo on FEV1 in Japanese patients with COPD. The results for some of the secondary variables (IC and PEF) indicated a trend towards larger improvements at higher dosages. All dosages of formoterol were well tolerated in Japanese patients.

Content from these authors
© 2008 by The Japanese Society of Internal Medicine
Previous article Next article
feedback
Top